Bloomberg on MSN8mon
GSK’s New Vaccine Kept the Boss in Her Job — and an Activist at Baythe chief executive officer of GSK Plc found her remedy in a product almost 60 years in the making. A vaccine breakthrough ...
GSK plans five new product approvals by 2025, highlights strong specialty growth, and acquires IDRx for $1 billion to expand its oncology portfolio.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback